Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

SELL
$41.75 - $54.5 $50.3 Million - $65.7 Million
-1,205,400 Reduced 46.38%
1,393,600 $71.4 Million
Q3 2022

Nov 14, 2022

SELL
$43.76 - $53.42 $6.35 Million - $7.75 Million
-145,000 Reduced 5.28%
2,599,000 $114 Million
Q2 2022

Aug 15, 2022

SELL
$46.53 - $55.17 $54 Million - $64.1 Million
-1,161,500 Reduced 29.74%
2,744,000 $144 Million
Q1 2022

May 16, 2022

BUY
$45.75 - $56.69 $59 Million - $73.1 Million
1,290,100 Added 49.33%
3,905,500 $202 Million
Q4 2021

Feb 14, 2022

BUY
$41.32 - $61.25 $108 Million - $160 Million
2,615,400 New
2,615,400 $154 Million
Q1 2021

May 17, 2021

SELL
$33.49 - $37.77 $121 Million - $137 Million
-3,616,600 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$33.47 - $42.56 $121 Million - $154 Million
3,616,600 New
3,616,600 $133 Million
Q2 2020

Aug 14, 2020

SELL
$30.12 - $36.54 $90.7 Million - $110 Million
-3,012,100 Closed
0 $0
Q1 2020

May 15, 2020

BUY
$27.03 - $38.62 $81.4 Million - $116 Million
3,012,100 New
3,012,100 $98.3 Million
Q1 2019

May 15, 2019

SELL
$37.5 - $41.2 $22.6 Million - $24.8 Million
-602,200 Closed
0 $0
Q4 2018

Feb 14, 2019

SELL
$38.47 - $43.86 $2.56 Million - $2.92 Million
-66,500 Reduced 9.94%
602,200 $26.3 Million
Q3 2018

Nov 14, 2018

SELL
$34.47 - $41.81 $10.8 Million - $13.1 Million
-313,300 Reduced 31.9%
668,700 $29.5 Million
Q4 2017

Feb 14, 2018

SELL
$33.26 - $35.29 $49.1 Million - $52.1 Million
-1,476,800 Reduced 60.06%
982,000 $35.6 Million
Q3 2017

Nov 14, 2017

BUY
$31.0 - $34.15 $76.2 Million - $84 Million
2,458,800
2,458,800 $87.8 Million

Others Institutions Holding PFE

About PFIZER INC


  • Ticker PFE
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 5,612,349,952
  • Market Cap $149B
  • Description
  • Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under ...
More about PFE
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.